Frequently Asked Questions
Resources
State, territorial, and local public health officials along with individual sites of care looking for assistance with operationalizing the administration of bamlanivimab and etesevimab may view the Bamlanivimab and Etesevimab Antibody Playbook.
These PDFs and links will help provide more details of Eli Lilly’s efforts to respond to the COVID-19 pandemic.
Fact Sheet for Healthcare Providers
Hospital/Infusion Site Checklist
These PDFs contain information for patients regarding COVID-19 and treatment options.
Patient COVID-19 Testing Education Guide
External Resources
These hyperlinks will take the viewer to a website external to Lilly.com
Utilization of COVID-19 Antibodies (National Governors Association)
National Infusion Center Association (NICA)
How-To-Use-NICA-Locator (Providers)
How-To-Use-NICA-Locator (Prescribers and Patients)
PHE COVID-19 Monoclonal Antibody Therapeutics Digital Toolkit
Department of Health & Human Services Monoclonal Antibody Playbook
Project Echo mAb Educational Mini-Series
CMS Monoclonal Antibody Coverage
World Health Organization (WHO)
Centers for Disease Control and Prevention (CDC)
References 1. Centers for Disease Control and Prevention (CDC). Interim clinical considerations for use of mRNA COVID-19 vaccines currently authorized in the United States. Updated January 21, 2021. Accessed January 23, 2021. https://www.cdc.gov/vaccines/covid-19/info-by-product/clinicalconsiderations.html. 2. Clem AS. Fundamentals of vaccine immunology. J Glob Infect Dis. 2011;3(1):73-78. http://dx.doi.org/10.4103/0974-777X.77299. 3. Slifka MK, Amanna IJ. Passive immunization. Plotkin's Vaccines. 2018;84-95.e10. http://dx.doi.org/10.1016/B978-0-323-35761-6.00008-0.